semaglutide hangover What to Expect in Your First Month on Semaglutide and NAD+ Truth, Safety

This research highlights that there are several studies under development that may bring additional results in the continuation or replication of the use of SMG in patients with obesity and/or DM2 but also investigate new combinations (e.g., combination with dehydrated cannabidiolNCT06648031) compared to new drugs (NCT06649344, NCT06604624, NCT06579105, NCT06577090, NCT06497049, NCT06282458, and NCT05616013) and may even expand the indications for other pathological conditions (associated or not with obesity or DM2), such as steroid-induced diabetes (NCT06318442), acute myocardial infarction (NCT06557811), autosomal dominant polycystic kidney disease (NCT06582875), steatohepatitis associated with metabolic dysfunction (NCT06492330 and NCT06374875), obesity-related asthma (NCT05254314), cystic fibrosis (NCT05788965), advanced interstitial lung disease (NCT05746039), psoriasis vulgaris (NCT06475586), systemic scleroderma (NCT06149260), idiopathic intracranial hypertension (NCT06361823 and NCT06027567), post-acute stroke (NCT05630586 and NCT05920889), neuroleptic-related prediabetes in individuals with schizophrenia (NCT05193578), Alzheimers (NCT06072963 and NCT05891496), functional hypogonadism (NCT06489457), polycystic ovary syndrome (NCT05646199, NCT05702905, NCT06222437, and NCT05819853), endometrial hyperplasia (NCT05829460), Klinefelters syndrome (NCT05586802), or even in alcohol consumption disorder (NCT05520775, NCT05891587, NCT05895643, and NCT05892432), opioid use (NCT06548490), or cocaine use with and without human immunodeficiency virus (NCT06691243), among many other potential therapeutic indications

Subgroup analyses revealed important differences based on comparator drugs: GLP-1RAs demonstrated greater effectiveness than SGLT2 inhibitors in preventing MALOs (IRR: 0.93, 95%CI: 0.87-0.99, P = 0.043), than DPP-4 inhibitors in preventing hepatic decompensation events (IRR: 0.74, 95%CI: 0.66-0.83, P = 0.003), and than insulin therapy in averting HCC development (IRR: 0.32, 95%CI: 0.13-0.80, P = 0.033) [64]

The Centers for Disease Control and Prevention (CDC) offers a chart showing recommended weight gain during pregnancy based on pre-pregnancy body mass index (BMI)

Curr Opin Environ Sci Health

The literature is conflicting on this topic, and although in vitro studies in obese mice have shown a positive effect of semaglutide in promoting muscle protein synthesis, increasing the relative proportion of skeletal muscle, and improving muscle function [119, 120], a synergistic dietary strategy such as the MD may help mitigate this concern and optimise the quality of weight loss